Biomarkers of tubulointerstitial damage and function in type 1 diabetes

Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objective To evaluate biomarkers of renal tubulointerstitial damage and function in type 1 diabetes with and without diabetic kidney disease. Research design and methods Cross-sectional case-control study of Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study participants. Cases (N=43) had incident persistent estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 with urinary albumin excretion >300 mg/24 hour. Controls (N=43) had persistent eGFR >90 mL/min/1.73 m 2 and urinary albumin excretion <30 mg/24 hour. Urinary and plasma biomarkers reflecting tubular injury, inflammation, fibrosis, secretion, and synthetic function were measured from stored specimens collected at the first study visit with reduced eGFR (for case participants) or the corresponding study year (for control participants). Results Mean (SD) age was 51 (9) and 50 (8) years for case and control participants, and mean (SD) duration of diabetes was 30 (6) and 30 (5) years, respectively. Mean (SD) eGFR was 39 (14) and 103 (9) mL/min/1.73 m 2 for case and control participants, and mean (SD) albumin excretion rate was 1978 (2914) and 10 (7) mg/day, respectively. Comparing cases with controls, significant differences were observed in each measured biomarker, including urine epidermal growth factor (mean 5.3 vs 21.2 μg/g creatinine for case vs control participants, respectively), urine monocyte chemoattractant protein-1 (596 vs 123 ng/g creatinine), urine galectin-3 (168 vs 52 μg/g creatinine), plasma soluble tubular necrosis factor receptor-1 (3695 vs 1022 pg/mL), plasma galectin-3 (21.3 vs 11.0 ng/mL), urinary clearances of hippurate (70 vs 167 mL/min) and cinnamoylglycine (77 vs 317 mL/min), and plasma arginine-citrulline ratio (5.6 vs 7.7 μg/μg), each P<0.001. Conclusions Marked abnormalities in biomarkers of kidney tubular injury, inflammation, fibrosis, secretion, and synthetic function accompany reduced eGFR and albuminuria in type 1 diabetes. Trial registration number NCT00360893, NCT00360815.

Original languageEnglish (US)
Article numbere000461
JournalBMJ Open Diabetes Research and Care
Volume5
Issue number1
DOIs
StatePublished - Nov 1 2017

Fingerprint

Glomerular Filtration Rate
Type 1 Diabetes Mellitus
Biomarkers
Galectin 3
Creatinine
Urine
Diabetes Complications
Albumins
Fibrosis
Inflammation
Kidney
Citrulline
Albuminuria
Chemokine CCL2
Wounds and Injuries
Diabetic Nephropathies
Epidermal Growth Factor
Arginine
Case-Control Studies
Epidemiology

Keywords

  • biomarkers
  • chronic kidney disease
  • type 1

Cite this

Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group (2017). Biomarkers of tubulointerstitial damage and function in type 1 diabetes. BMJ Open Diabetes Research and Care, 5(1), [e000461]. https://doi.org/10.1136/bmjdrc-2017-000461

Biomarkers of tubulointerstitial damage and function in type 1 diabetes. / Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group.

In: BMJ Open Diabetes Research and Care, Vol. 5, No. 1, e000461, 01.11.2017.

Research output: Contribution to journalArticle

Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group 2017, 'Biomarkers of tubulointerstitial damage and function in type 1 diabetes', BMJ Open Diabetes Research and Care, vol. 5, no. 1, e000461. https://doi.org/10.1136/bmjdrc-2017-000461
Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Biomarkers of tubulointerstitial damage and function in type 1 diabetes. BMJ Open Diabetes Research and Care. 2017 Nov 1;5(1). e000461. https://doi.org/10.1136/bmjdrc-2017-000461
Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. / Biomarkers of tubulointerstitial damage and function in type 1 diabetes. In: BMJ Open Diabetes Research and Care. 2017 ; Vol. 5, No. 1.
@article{fa0b6b5570be41bea4156996865dfbd4,
title = "Biomarkers of tubulointerstitial damage and function in type 1 diabetes",
abstract = "Objective To evaluate biomarkers of renal tubulointerstitial damage and function in type 1 diabetes with and without diabetic kidney disease. Research design and methods Cross-sectional case-control study of Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study participants. Cases (N=43) had incident persistent estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 with urinary albumin excretion >300 mg/24 hour. Controls (N=43) had persistent eGFR >90 mL/min/1.73 m 2 and urinary albumin excretion <30 mg/24 hour. Urinary and plasma biomarkers reflecting tubular injury, inflammation, fibrosis, secretion, and synthetic function were measured from stored specimens collected at the first study visit with reduced eGFR (for case participants) or the corresponding study year (for control participants). Results Mean (SD) age was 51 (9) and 50 (8) years for case and control participants, and mean (SD) duration of diabetes was 30 (6) and 30 (5) years, respectively. Mean (SD) eGFR was 39 (14) and 103 (9) mL/min/1.73 m 2 for case and control participants, and mean (SD) albumin excretion rate was 1978 (2914) and 10 (7) mg/day, respectively. Comparing cases with controls, significant differences were observed in each measured biomarker, including urine epidermal growth factor (mean 5.3 vs 21.2 μg/g creatinine for case vs control participants, respectively), urine monocyte chemoattractant protein-1 (596 vs 123 ng/g creatinine), urine galectin-3 (168 vs 52 μg/g creatinine), plasma soluble tubular necrosis factor receptor-1 (3695 vs 1022 pg/mL), plasma galectin-3 (21.3 vs 11.0 ng/mL), urinary clearances of hippurate (70 vs 167 mL/min) and cinnamoylglycine (77 vs 317 mL/min), and plasma arginine-citrulline ratio (5.6 vs 7.7 μg/μg), each P<0.001. Conclusions Marked abnormalities in biomarkers of kidney tubular injury, inflammation, fibrosis, secretion, and synthetic function accompany reduced eGFR and albuminuria in type 1 diabetes. Trial registration number NCT00360893, NCT00360815.",
keywords = "biomarkers, chronic kidney disease, type 1",
author = "{Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group} and {De Boer}, {Ian H.} and Xiaoyu Gao and Ionut Bebu and Hoofnagle, {Andrew N.} and Lachin, {John M.} and Andrew Paterson and Perkins, {Bruce A.} and Saenger, {Amy K.} and Steffes, {Michael W.} and Bernard Zinman and Molitch, {Mark E.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1136/bmjdrc-2017-000461",
language = "English (US)",
volume = "5",
journal = "BMJ Open Diabetes Research and Care",
issn = "2052-4897",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Biomarkers of tubulointerstitial damage and function in type 1 diabetes

AU - Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group

AU - De Boer, Ian H.

AU - Gao, Xiaoyu

AU - Bebu, Ionut

AU - Hoofnagle, Andrew N.

AU - Lachin, John M.

AU - Paterson, Andrew

AU - Perkins, Bruce A.

AU - Saenger, Amy K.

AU - Steffes, Michael W.

AU - Zinman, Bernard

AU - Molitch, Mark E.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Objective To evaluate biomarkers of renal tubulointerstitial damage and function in type 1 diabetes with and without diabetic kidney disease. Research design and methods Cross-sectional case-control study of Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study participants. Cases (N=43) had incident persistent estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 with urinary albumin excretion >300 mg/24 hour. Controls (N=43) had persistent eGFR >90 mL/min/1.73 m 2 and urinary albumin excretion <30 mg/24 hour. Urinary and plasma biomarkers reflecting tubular injury, inflammation, fibrosis, secretion, and synthetic function were measured from stored specimens collected at the first study visit with reduced eGFR (for case participants) or the corresponding study year (for control participants). Results Mean (SD) age was 51 (9) and 50 (8) years for case and control participants, and mean (SD) duration of diabetes was 30 (6) and 30 (5) years, respectively. Mean (SD) eGFR was 39 (14) and 103 (9) mL/min/1.73 m 2 for case and control participants, and mean (SD) albumin excretion rate was 1978 (2914) and 10 (7) mg/day, respectively. Comparing cases with controls, significant differences were observed in each measured biomarker, including urine epidermal growth factor (mean 5.3 vs 21.2 μg/g creatinine for case vs control participants, respectively), urine monocyte chemoattractant protein-1 (596 vs 123 ng/g creatinine), urine galectin-3 (168 vs 52 μg/g creatinine), plasma soluble tubular necrosis factor receptor-1 (3695 vs 1022 pg/mL), plasma galectin-3 (21.3 vs 11.0 ng/mL), urinary clearances of hippurate (70 vs 167 mL/min) and cinnamoylglycine (77 vs 317 mL/min), and plasma arginine-citrulline ratio (5.6 vs 7.7 μg/μg), each P<0.001. Conclusions Marked abnormalities in biomarkers of kidney tubular injury, inflammation, fibrosis, secretion, and synthetic function accompany reduced eGFR and albuminuria in type 1 diabetes. Trial registration number NCT00360893, NCT00360815.

AB - Objective To evaluate biomarkers of renal tubulointerstitial damage and function in type 1 diabetes with and without diabetic kidney disease. Research design and methods Cross-sectional case-control study of Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study participants. Cases (N=43) had incident persistent estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 with urinary albumin excretion >300 mg/24 hour. Controls (N=43) had persistent eGFR >90 mL/min/1.73 m 2 and urinary albumin excretion <30 mg/24 hour. Urinary and plasma biomarkers reflecting tubular injury, inflammation, fibrosis, secretion, and synthetic function were measured from stored specimens collected at the first study visit with reduced eGFR (for case participants) or the corresponding study year (for control participants). Results Mean (SD) age was 51 (9) and 50 (8) years for case and control participants, and mean (SD) duration of diabetes was 30 (6) and 30 (5) years, respectively. Mean (SD) eGFR was 39 (14) and 103 (9) mL/min/1.73 m 2 for case and control participants, and mean (SD) albumin excretion rate was 1978 (2914) and 10 (7) mg/day, respectively. Comparing cases with controls, significant differences were observed in each measured biomarker, including urine epidermal growth factor (mean 5.3 vs 21.2 μg/g creatinine for case vs control participants, respectively), urine monocyte chemoattractant protein-1 (596 vs 123 ng/g creatinine), urine galectin-3 (168 vs 52 μg/g creatinine), plasma soluble tubular necrosis factor receptor-1 (3695 vs 1022 pg/mL), plasma galectin-3 (21.3 vs 11.0 ng/mL), urinary clearances of hippurate (70 vs 167 mL/min) and cinnamoylglycine (77 vs 317 mL/min), and plasma arginine-citrulline ratio (5.6 vs 7.7 μg/μg), each P<0.001. Conclusions Marked abnormalities in biomarkers of kidney tubular injury, inflammation, fibrosis, secretion, and synthetic function accompany reduced eGFR and albuminuria in type 1 diabetes. Trial registration number NCT00360893, NCT00360815.

KW - biomarkers

KW - chronic kidney disease

KW - type 1

UR - http://www.scopus.com/inward/record.url?scp=85056250763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056250763&partnerID=8YFLogxK

U2 - 10.1136/bmjdrc-2017-000461

DO - 10.1136/bmjdrc-2017-000461

M3 - Article

AN - SCOPUS:85056250763

VL - 5

JO - BMJ Open Diabetes Research and Care

JF - BMJ Open Diabetes Research and Care

SN - 2052-4897

IS - 1

M1 - e000461

ER -